Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection

Marco Ratta, Donia Skanji, Zhaoyang Teng, Gaëlle Saint‐Hilary, Mauro Gasparini, Pavel Mozgunov
Statistics in Medicine · Wiley · 2026-11-17 · DOI: 10.1002/sim.70790

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles